UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number: 001-40552
NYXOAH SA
(Translation of registrant’s name into English)
Rue Edouard Belin 12, 1435 Mont-Saint-Guibert,
Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note: Regulation S-T Rule 101(b)(1) only
permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private
issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission
or other Commission filing on EDGAR.
Nyxoah SA
On November 18, 2026, Nyxoah SA (the “Company”)
issued a press release, a copy of which is attached hereto as Exhibit 99.1.
The
information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section,
nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the
Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
Exhibits
| 99.1 |
Press Release, dated November 18, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
NYXOAH SA |
| |
|
|
| Date: November 18, 2026 |
By: |
/s/ Loic Moreau |
| |
Name: |
Loic Moreau |
| |
Title: |
Interim Chief Financial Officer |
Exhibit 99.1
INSIDE INFORMATION
REGULATED INFORMATION
Nyxoah Obtains
Default Decision Against Inspire Medical Systems in Unified Patent Court Case
Mont-Saint-Guibert,
Belgium – November 18, 2026, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah”
or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea
(OSA) through neuromodulation, today announced that the Court of First Instance of the Unified Patent Court (UPC) in Munich, Germany,
issued a decision by default in favor of Nyxoah. Nyxoah had filed an infringement case against Inspire Medical Systems at the UPC regarding
Nyxoah’s European Patent 2 760 534.
Nyxoah is currently
considering all options of enforcement.
About Nyxoah
Nyxoah
is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s
lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s
most common sleep disordered breathing condition that is associated with increased mortality risk
and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live
their life to its fullest.
Following the successful
completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext
Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark
approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in
competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study in 2024 and received
approval from the FDA in August 2025, with the treatment of CCC patients included in the warning section of our indications for use.
For more information,
please visit http://www.nyxoah.com.
Caution –
CE marked since 2019. FDA approved in August 2025 as prescription-only device.
Forward-looking
statements
Certain statements,
beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’
or management’s current expectations regarding the Genio system; the final outcome of any lawsuit or legal procedure between Nyxoah
and Inspire Medical Systems; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of
the Genio system; the PMA supplement to the FDA and the timing and outcome of any FDA review; the Company's commercialization strategy
and growth in the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future
revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors
that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These
risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described
herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors”
section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange
Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including,
but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly
from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are
not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the
future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press
release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation
or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change
in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based,
except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its
subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements
are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in
this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements,
which speak only as of the date of this press release.
Contacts:
Nyxoah
Loïc Moreau, Interim CFO
IR@nyxoah.com
Rémi Renard, Head of Investor
Relations & Corporate Communication
IR@nyxoah.com